To 1) measure and improve the quality of care, 2) determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches, 3) understand risk factors for outcomes , and 4) facilitate funded clinical trials of new therapies and collaboration within the pulmonary arterial hypertension (PAH) community.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Jimmy Ford
Medicine-Pulmonary
Clinical or Medical
Registry
Lungs and Breathing
16-1137
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
